Ownership Capital B.V. Has $266.11 Million Stock Holdings in Edwards Lifesciences Co. (NYSE:EW)

Ownership Capital B.V. raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 21.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,489,915 shares of the medical research company’s stock after purchasing an additional 613,817 shares during the quarter. Edwards Lifesciences accounts for about 5.9% of Ownership Capital B.V.’s holdings, making the stock its 5th biggest holding. Ownership Capital B.V. owned approximately 0.58% of Edwards Lifesciences worth $266,106,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also bought and sold shares of EW. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $34,000. Operose Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock worth $44,000 after acquiring an additional 452 shares during the last quarter. SRS Capital Advisors Inc. lifted its holdings in shares of Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after acquiring an additional 474 shares during the last quarter. NBC Securities Inc. bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $52,000. Finally, ORG Partners LLC bought a new stake in shares of Edwards Lifesciences in the 3rd quarter worth approximately $66,000. 79.46% of the stock is currently owned by institutional investors.

Insider Activity

In related news, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $85.62, for a total value of $2,311,740.00. Following the transaction, the vice president now owns 34,814 shares of the company’s stock, valued at $2,980,774.68. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CFO Scott B. Ullem sold 7,255 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the transaction, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Catherine M. Szyman sold 27,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $85.62, for a total transaction of $2,311,740.00. Following the completion of the transaction, the vice president now directly owns 34,814 shares in the company, valued at approximately $2,980,774.68. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last 90 days. 1.29% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on EW shares. Piper Sandler boosted their price objective on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a report on Friday. Evercore ISI reduced their price objective on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a research report on Friday. Citigroup upped their price objective on shares of Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. Stifel Nicolaus upped their price objective on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday. Finally, Bank of America upgraded shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating in a report on Thursday, March 7th. One equities research analyst has rated the stock with a sell rating, seven have given a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $93.33.

Edwards Lifesciences Stock Performance

Shares of NYSE EW traded down $1.58 during trading on Friday, reaching $86.43. 4,979,943 shares of the company traded hands, compared to its average volume of 2,883,164. The firm has a 50 day simple moving average of $90.28 and a 200-day simple moving average of $78.85. The company has a quick ratio of 2.40, a current ratio of 3.38 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $52.02 billion, a PE ratio of 37.25, a P/E/G ratio of 4.36 and a beta of 1.05. Edwards Lifesciences Co. has a 52-week low of $60.57 and a 52-week high of $96.12.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 23.34%. Equities research analysts anticipate that Edwards Lifesciences Co. will post 2.76 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.